[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-metastatic-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-metastatic-colorectal-cancer":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100508764","circulating-tumor-dna-methylation-guided-postoperative-follow-up-strategy-for-non-metastatic-colorectal-cancer-100508764",false,"NCT05904665","Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer","Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer: a Multicenter, Prospective, Randomized Controlled Cohort Study (FIND Trial)","Inclusion Criteria:\n\n1. Age ≥ 18 years old, regardless of gender;\n2. Personal status (PS) score as over 80 or Eastern Cooperative Oncology Group (ECOG) score as 0 \\~ 2;\n3. Preoperative imaging examinations reveal no definite distant metastatic lesions, and postoperative pTNM staging confirms patients with stage I to III colorectal cancer;\n4. Radical operation performed ;\n5. With expected survival of more than 12 months;\n6. The subjects (or their legal representative \u002F Guardian) must sign the informed consent form, indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study.\n\nExclusion Criteria:\n\n1. Blood transfusion performed during operation or within 2 weeks before operation;\n2. Incomplete baseline samples, including preoperative plasma samples;\n3. Two consecutive test points missing or three plasma samples missing in total before a positive ctDNA time point;\n4. Pregnant or lactating women who have fertility and do not take adequate contraceptive measures;\n5. Have a history of other malignant tumors within 5 years, except cured cervical carcinoma in situ or non melanoma skin cancer;\n6. Primary brain tumor or central nerve metastasis is not under control, with obvious intracranial hypertension or neuropsychiatric symptoms;\n7. Patients with the following serious or uncontrollable diseases: severe heart disease, the condition is still unstable after treatment, including myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment; definite neuropathy or psychosis, including dementia or seizures; severe or uncontrolled infection; active disseminated intravascular coagulation and obvious bleeding tendency;\n8. Significant impairment of important organ function;\n9. Other conditions in which the investigator believes that the patient should not participate in this trial.","ALL","18 Years","80 Years",{"count":20,"type":21},584,"ESTIMATED","INTERVENTIONAL",[24],"NA","Colorectal cancer (CRC) is one of the most common gastrointestinal tumors. According to the latest cancer report, the incidence and mortality rates of CRC are both ranked top 5 among malignant tumors worldwide and continue to rise. Patients who receive treatment in the early stage (stage I) have a 5-year survival rate of approximately 90%. However, for high-risk stage II and III colorectal cancer patients, the 5-year survival rate is only 40%-70%, and almost half of the patients experience postoperative recurrence and metastasis.\n\nCirculating tumor DNA (ctDNA) is a small fraction of total cell-free DNA (cfDNA) in peripheral blood circulation, carrying tumor-specific genetic and epigenetic information. It can usually be detected in the serum or plasma of tumor patients in peripheral blood. Studies have shown that methylation detection of plasma ctDNA can be used for predicting the efficacy and prognosis of tumor postoperatively, as well as for dynamic monitoring.\n\nCurrent methods for monitoring CRC recurrence include testing for carcinoembryonic antigen (CEA) in blood and periodic computed tomography (CT) scans. However, due to the low sensitivity of CEA and the radiation and cost limitations of CT examination, the disease status of postoperative CRC patients cannot be well-monitored.\n\nctDNA is a promising biomarker for monitoring the recurrence and metastasis of CRC. Research results have shown that ctDNA can be detected in nearly all subjects before surgery, and the changes in ctDNA levels are related to the extent of surgical resection. The detection of ctDNA after surgery generally indicates recurrence within one year. ctDNA may be a more reliable and sensitive indicator than the current standard biomarker CEA, providing a window for early intervention.\n\nThis multicenter, prospective, and randomized controlled cohort study uses a single-tube methylation-specific quantitative PCR (mqMSP) detection, which detects 10 different methylation markers and can quantitatively analyze plasma samples containing tumor DNA as low as 0.01%. This study will use the ctDNA methylation detection technology to conduct quantitative detection of ctDNA methylation in the plasma of enrolled patients, hoping to predict the recurrence and metastasis risk of patients at an earlier stage through ctDNA changes, and to explore the value of ctDNA detection in guiding postoperative follow-up for non-metastatic CRC.",[27,28],"Non-metastatic Colorectal Cancer","Circulating Tumor DNA Methylation","RECRUITING","2025-09-12",{"date":32,"type":33},"2025-09-18","ACTUAL",{"date":35,"type":33},"2023-06-15",{"date":37,"type":21},"2028-06",{"name":39,"class":40},"Fudan University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100473647","role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer-100473647","NCT05447611","Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.","Role of Empathy in the Outcome of Curative Treatment of Non-metastatic Colorectal Cancer. Prospective Multicenter Longitudinal Study in Two Departments Covered by the Calvados Cancer Registry.","EMPACOL","Inclusion Criteria:\n\nPatients aged 18 to 75 years, French-speaking, affiliated to a social security system, having received informed information and not having expressed an unfavorable opinion to participate; carriers of non-metastatic and uncomplicated CRC (without occlusion\u002F perforation\u002Fbleeding), requiring elective therapeutic management. The included patients have a cognitive state capable of understanding and completing the questionnaires (autonomous completion).\n\nExclusion Criteria:\n\nPatients who were minors or older than 80 years, residing in a department outside Calvados or Manche, presenting a CRC other than adenocarcinoma and all metastatic forms or requiring emergency surgery (perforation, hemorrhage, occlusion), exclusive endoscopic treatment, or a missed-CRC discovered after surgery for non-oncological indications.\n\nPatients with another neoplastic disease under treatment and\u002For evolving, patients with a history of inflammatory bowel disease (Crohn's disease, ulcerative colitis) and\u002For hereditary disease predisposing to CRC (Lynch syndrome, familial polyposis) or with severe cognitive impairment preventing proper comprehension of the questionnaires. Pregnant women will be excluded.",true,{"count":52,"type":21},250,"OBSERVATIONAL","The aim of project EMPACOL will be to investigate, while taking into consideration the clinical factors known and well described in the literature, among the non-clinical factors, in particular, patient-healthcare personnel (HCP) relationship, a link between HCP's empathy perceived by the patient, and the results of the curative treatment of non-metastatic colorectal cancer, throughout the patient's care.",[27,56,57,58,59],"Empathy","Morbidity","Morality","Quality of Life",[61,62,63],"colorectal cancer","empathy","outcomes","NOT_YET_RECRUITING","2022-07-06",{"date":67,"type":33},"2022-07-07",{"date":69,"type":21},"2022-09",{"date":71,"type":21},"2029-09",{"name":73,"class":40},"University Hospital, Caen",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100434579","interest-of-the-immunoscore-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer-100434579","NCT04938986","Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer","Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer : Prospective Cohort Comparing the Recommandation for Patient Care According to the Immunoscore® With the Standard Care Decision.","Inclusion Criteria:\n\n* age between 18 and 80 inclusive;\n* histologically confirmed colon adenocarcinoma;\n* having undergone a curative resection of stage I, II or III colorectal cancer;\n* diagnosed T1 \u002F T2 \u002F T3 \u002F T4 and N0 \u002F N1 \u002F N2;\n* eligible to receive 6 months of adjuvant chemotherapy;\n* having given free, informed and written consent;\n* agreeing to the use of a tumor sample for research purposes;\n* being affiliated to a social security system.\n\nExclusion Criteria:\n\n* pregnant or breastfeeding women\n* legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study.\n* history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled\n* person subject to a safeguard measure.",{"count":82,"type":21},100,[24],"Evaluate the patient care recommandation induced by the IMMUNOSCORE® result",[86],"Non Metastatic Colorectal Cancer","2022-04-12",{"date":89,"type":33},"2022-04-13",{"date":91,"type":33},"2022-04-04",{"date":93,"type":21},"2028-04",{"name":95,"class":40},"Hospital St. Joseph, Marseille, France",2]